Dr. Andres Alejandro Redondo, MD

Dr. Redondo practices at South Florida Pulmonary & Critical Care Associates P.A. in Shenandoah, Florida.

Dr. Redondo's NPI, 1558369165, was assigned on July 8, 2005. Dr. Redondo graduated from Pontificia Universidad Católica Madre y Maestra in 1982. Dr. Redondo holds Florida license ME0045903.

Dr. Redondo's primary practice is South Florida Pulmonary & Critical Care Associates P.A., at 3181 Sw 22nd St, Shenandoah, FL 33145 in Miami-Dade County. The practice phone is (305) 567-1999.

Dr. Redondo's primary practice is South Florida Pulmonary & Critical Care Associates P.A. in Shenandoah, Florida. The medical group on file is South Florida Pulmonary & Critical Care Associates. Dmand AI also links Dr. Redondo to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Redondo practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Redondo's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Redondo is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Redondo's licenses on file in 2 states: Florida and Iowa.

Dmand AI lists asthma, bronchitis, chronic obstructive pulmonary disease (COPD), pneumonia, pulmonary fibrosis, sleep apnea and tobacco use among the conditions Dr. Redondo treats.

CMS data shows 963 Medicare services from Dr. Redondo across 9 procedure codes in 2024, for 190 Medicare patients. Medicare paid $64,801 for them. Every service was in an office.

CMS counts 190 Medicare patients who saw Dr. Redondo in 2024. The largest group is 75 to 84, with 72 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 65% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Redondo's median patient age at 70, with 53% women.

In 2024, Dr. Redondo wrote 15,755 Medicare Part D claims for 1,772 patients. CMS names the drug for 15,570 of them, across 52 drugs with 11 or more claims each, at $4,088,153 in total drug cost. In 2023, CMS named 15,497 claims across 53 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Redondo for performance year 2024, reported as part of a group. Dr. Redondo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Redondo as offering telehealth.

Dmand AI links Dr. Redondo to 4 clinical trials, 4 of them phase 2 studies. Conditions studied include Granulosa Cell Tumor, Ichthyosis, X-Linked and Ovarian Neoplasms. Grupo Espanol de Investigacion en Sarcomas sponsors the most, 2.

CMS Open Payments shows 333 general payments to Dr. Redondo from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. GlaxoSmithKline, LLC. paid the most, $14,550.

Dr. Redondo graduated from Pontificia Universidad Católica Madre y Maestra in 1982.

Dr. Redondo is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.